Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Crovalimab

First Posted Date: 2021-06-03

Last Posted Date: 2025-04-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT04912869

Locations: 🇮🇹
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi, Verona, Veneto, Italy
🇰🇪
International Cancer Institute (ICI), Eldoret, Kenya
🇰🇪
Gertrude's Children Hospital, Nairobi, Kenya

and more 13 locations

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

Phase 3

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: RO7496998

First Posted Date: 2021-05-17

Last Posted Date: 2024-01-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 216

Registration Number: NCT04889040

Locations: 🇯🇵
Higashiosaka city Medical Center, Higashiosaka-Shi, Japan
🇷🇴
County Hospital Caracal, Caracal, Romania
🇧🇪
Maison Médicale La Brèche, Châtelineau, Belgium

and more 47 locations

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab Emtansine
Drug: Atezolizumab
Drug: Placebo
Drug: Trastuzumab

First Posted Date: 2021-05-05

Last Posted Date: 2025-03-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1188

Registration Number: NCT04873362

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou City, China
🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, China
🇨🇳
The First Affilicated Hospital, Sun Yat-sen University, Guangzhou, China

and more 238 locations

A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants

Phase 1

Completed

Conditions: Angelman Syndrome

Interventions: Drug: RO7248824

First Posted Date: 2021-04-28

Last Posted Date: 2022-09-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 21

Registration Number: NCT04863794

Locations: 🇳🇱
Pra International Group B.V, Groningen, Netherlands

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3

Active, not recruiting

Conditions: Atypical Hemolytic Uremic Syndrome

Interventions: Drug: Crovalimab

First Posted Date: 2021-04-27

Last Posted Date: 2025-06-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 83

Registration Number: NCT04861259

Locations: 🇮🇳
Medanta-The Medicity, Gurgaon, Haryana, India
🇺🇸
University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Univ of CA San Francisco, San Francisco, California, United States

and more 52 locations

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: RO7300490
Drug: Atezolizumab

First Posted Date: 2021-04-23

Last Posted Date: 2024-02-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT04857138

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇬🇧
Western General Hospital; Edinburgh Cancer Center, Edinburgh, United Kingdom

and more 8 locations

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Paclitaxel

First Posted Date: 2021-04-06

Last Posted Date: 2025-03-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT04832854

Locations: 🇪🇸
ICO L'Hospitalet, L Hospitalet De Llobregat, Barcelona, Spain
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
UniversitätsSpital Zürich, Zürich, Switzerland

and more 19 locations

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: RO7122290
Drug: Cibisatamab
Drug: Obinutuzumab

First Posted Date: 2021-04-01

Last Posted Date: 2025-01-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 54

Registration Number: NCT04826003

Locations: 🇩🇰
Rigshospitalet, København Ø, Denmark
🇪🇸
Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital del Mar, Barcelona, Spain

and more 9 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1

Recruiting

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Interventions: Drug: Giredestrant
Drug: Abemaciclib
Drug: Ipatasertib
Drug: Inavolisib
Drug: Ribociclib
Drug: Everolimus
Drug: Samuraciclib
Drug: Atezolizumab
Drug: PH FDC SC
Drug: Palbociclib

First Posted Date: 2021-03-17

Last Posted Date: 2025-06-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 316

Registration Number: NCT04802759

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇮🇱
Rabin MC, Petach Tikva, Israel
🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 25 locations

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Phase 2

Terminated

Conditions: Autoimmune Hepatitis
Autoimmune Chronic Hepatitis

Interventions: Other: Placebo
Drug: RO7049665

First Posted Date: 2021-03-10

Last Posted Date: 2023-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT04790916

Locations: 🇦🇺
The Alfred Hospital - Professor Stuart Roberts' Clinic - The Alfred Centre Location, Melbourne, Victoria, Australia
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪
Martin Zeitz Centrum für Seltene Erkrankungen ZSE Hamburg, Hamburg, Germany

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy